Indeed, if on the one hand the concomitant high SIRT6 and low TBX3 expression predicts better prognosis in basal-like breast cancer, on the other, it is indicative of poor prognosis in HER2-positive breast cancer patients. This evidence concerns the gene TBX3 and breast carcinoma.